Ramzi Benamar - BELLUS Health Chief Officer
| BLUDelisted Stock | USD 14.74 0.00 0.00% |
Insider
Ramzi Benamar is Chief Officer of BELLUS Health
| Age | 50 |
| Phone | 450 680 4500 |
| Web | https://www.bellushealth.com |
BELLUS Health Management Efficiency
The company has Return on Asset of (0.167) % which means that on every $100 spent on assets, it lost $0.167. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2676) %, meaning that it generated no profit with money invested by stockholders. BELLUS Health's management efficiency ratios could be used to measure how well BELLUS Health manages its routine affairs as well as how well it operates its assets and liabilities.BELLUS Health has 1.28 M in debt with debt to equity (D/E) ratio of 0.0, which may show that the company is not taking advantage of profits from borrowing. BELLUS Health has a current ratio of 11.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for BELLUS to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Rolph | Akero Therapeutics | 70 | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| Justin Klee | Amylyx Pharmaceuticals | 33 | |
| Heow Tan | Biomea Fusion | 65 | |
| Naomi Cretcher | Biomea Fusion | N/A | |
| Stephen MD | Kura Oncology | 52 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Laura Carter | Gossamer Bio | 57 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Kristian MBA | Viridian Therapeutics | 49 | |
| Thomas Butler | Biomea Fusion | 43 | |
| Carrie MBA | Viridian Therapeutics | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Lara Meisner | Viridian Therapeutics | 50 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| MD MBA | Kalvista Pharmaceuticals | 51 | |
Management Performance
| Return On Equity | -0.27 | |||
| Return On Asset | -0.17 |
BELLUS Health Leadership Team
Elected by the shareholders, the BELLUS Health's board of directors comprises two types of representatives: BELLUS Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BELLUS. The board's role is to monitor BELLUS Health's management team and ensure that shareholders' interests are well served. BELLUS Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BELLUS Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sebastien Roy, Co Sec | ||
| Tony Matzouranis, Sr Devel | ||
| Denis Garceau, Chief Officer | ||
| Roberto Bellini, CEO Pres | ||
| Daniel Matthews, Director Communications | ||
| Catherine MD, Chief Officer | ||
| Ramzi Benamar, Chief Officer | ||
| FFPM MBBCh, Chief Officer |
BELLUS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BELLUS Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | |||
| Return On Asset | -0.17 | |||
| Current Valuation | 1.56 B | |||
| Shares Outstanding | 126.81 M | |||
| Shares Owned By Insiders | 10.26 % | |||
| Shares Owned By Institutions | 90.41 % | |||
| Number Of Shares Shorted | 6.65 M | |||
| Price To Earning | (15.27) X | |||
| Price To Book | 3.02 X | |||
| Price To Sales | 75,790 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in BELLUS Stock
If you are still planning to invest in BELLUS Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BELLUS Health's history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |